ABIVAX (EPA:ABVX) Abivax announces the release of its 2021Â half-year financial report
Transparency directive : regulatory news
30/09/2021 18:00
DGAP-News: ABIVAX
/ Key word(s): Half Year Report
Abivax announces the release of its 2021 half-year financial report
30.09.2021 / 18:00
The issuer is solely responsible for the content of this announcement.
Abivax announces the release of its 2021 half-year financial report
PARIS, France, September 30, 2021 - 6:00 pm (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announces the publication of its 2021 half-year financial report. This document is available in electronic version on the website of the company (www.abivax.com - "Investors") and on the website of the French financial markets authority, AMF (www.amf-france.org).
*****
About Abivax (www.abivax.com)
Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the physiological inflammation and immunological pathways to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe chronic inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.
Contacts
30.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
|
1237306 30.09.2021